CClinicalTrials.gg
CompletedNCT05661006ETOL-ElderlyUpdated Jun 22, 2023

ETOL-Elderly Study of the Efficiency of the Innovative Food Supplement in Elderly Adults

An interventional study of Use of food supplement and Use of placebo food supplement in Vitamin d Deficiency, Vitamin B 12 Deficiency and Protein Deficiency, sponsored by Nutrition Institute, Slovenia. Completed at 1 site in Slovenia. Open to participants aged 65 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Nutrition Institute, Slovenia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
65 Years to 95 Years
Sex
All
01

Study summary

The aim of this pilot study is to conduct a study on geriatric population in Slovenia (non-users of dietary supplements/medicines with vitamine D, vitamin B12 and protein) and assess deficiency of selected nutrients, and to investigate the efficiency of the innovative food supplement prototype in improving nutritional status of elderly adults.

Read the detailed description

The main objective is to show that in the geriatric population regular use of investigation food supplement would improve nutritional status. The study should provide answers to the following main questions: (1) Is regular use of investigated product beneficial for improving serum vitamin D levels in elderly population? (2) Is regular use of investigated product beneficial for increasing daily protein intake in elderly population? (3) Is regular use of investigated product beneficial for improving vitamin B12 status in elderly population?

02

Conditions studied

  • Vitamin d Deficiency
  • Vitamin B 12 Deficiency
  • Protein Deficiency
03

Who can participate

Ages eligible
65 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subject Informed consent form (ICF) is singed
  • Aged at least 65 at the time of the signature of ICF
  • A body mass index lower than 32 kg/m2
  • Willing to avoid a consumption supplementation with protein, vitamin D and vitamin B12 during the study
  • Willing to follow all study procedures, including attending all site visits (including blood sampling) and keeping a diary for using the product and six 24-hour dietary records (3x pre-intervention, 3x during last week of the intervention)

Exclusion criteria

Exclusion criteria:

  • Medical treatment with Vitamin D and/or Vitamin B12
  • Supplementation with protein, vitamin D and/or vitamin B12 during least 2 months
  • Known drug and/or alcohol abuse
  • Known lactose/gluten intolerances/food allergies
  • Inadequate veins (in the opinion of the investigator) or known contraindication for venous blood withdrawal
  • Have chronic bowel disease (ulcerative colitis, Chron's disease, stomach or duodenal ulcer, chronic inflammation of the stomach or duodenum)
  • Have acute gastrointestinal infection with vomiting and / or diarrhea
  • Have planned general anaesthesia or colonoscopy at the time of the study
  • Have malabsorption syndrome
  • Less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)
  • Have stomach or bowel resection
  • Do not have neat and functional teeth
  • Take regular or occasional laxative products
  • Use antacids (Rupurut / Rutacid / Talcit)
  • Mental incapacity that precludes adequate understanding or cooperation
  • Participation in another investigational study
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    Control group

    Subjects taking control product

    Dietary Supplement: Use of placebo food supplement

  • Experimental
    Active group

    Subjects taking active product

    Dietary Supplement: Use of food supplement

Interventions

  • Dietary supplementUse of food supplement

    On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day). Intervention end on day 56 ±3 (fasted condition): Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product

  • Dietary supplementUse of placebo food supplement

    On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end

05

What researchers measure

Primary outcomes

  1. Change in serum vitamin D levels will be determined

    Serum level of 25-OH-vitamin D will be measured before and after the intervention for each individual.

    Time frame: 56 days

Secondary outcomes

  1. Change in dietary protein intake will be determined

    Dietary protein intake will be estimated before and after the intervention for each individual, using 3x24h food records.

    Time frame: 56 days

  2. Change in serum vitamin B12 levels will be determined

    Serum level of vitamin B12 will be measured before and after the intervention for each individual.

    Time frame: 56 days

  3. Malnutrition at baseline

    Risks for malnutritition at baseline will be assessed using dietary records (3x24h food record: energy, protein and plasma concentration of 25-OH-D and vitamin B12.

    Time frame: baseline

06

Study locations

1 site
  • VIZERA
    Trzin, Slovenia
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05661006
Lead sponsor
Nutrition Institute, Slovenia
Collaborators
Vizera d.o.o., Frutarom Etol d.o.o., European Regional Development Fund
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Feb 20, 2020
Primary completion
May 5, 2020
Completion
Jun 29, 2020
Last update
Jun 22, 2023

Study contacts

Mojca Miholič, MD
principal investigator · Researcher

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion